Title
Category
Credits
Event date
Cost
NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
05/23/2025
$0.00
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course
  • Chronic Lymphocytic Leukemia
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
05/30/2025
$0.00
Join us for this dynamic, case-based, live symposium in collaboration with the NCCN to hear from an expert panel on current recommendations and emerging strategies for treating patients with CLL.
CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice
  • Breast Cancer
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
05/30/2025
$0.00
Join us for this engaging session led by expert oncology faculty to learn the latest evidence and recommendations with CDK4/6 inhibitors for breast cancer. Insights on how to best mitigate CDK4/6 inhibitor–related adverse events will also be highlighted.
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
  • Multiple Myeloma
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ABIM Medical Knowledge
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
05/31/2025
$0.00
Live satellite symposium with a panel of experts discussing current guidelines and latest clinical evidence for the management of patients with multiple myeloma including expert guidance to help inform treatment decisions and therapy sequencing.
Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers
  • Gastric/Esophageal Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
07/23/2025
$0.00
The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to treat this patient population effectively.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
08/14/2025
$0.00
With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.

Pages